alexa
Reach Us +1-217-403-9671
Downstream Processing Of Monoclonal Antibodies (MAbs): Challenges And Troubleshooting | 8200
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Downstream processing of Monoclonal Antibodies (MAbs): Challenges and troubleshooting

International Conference and Exhibition on Biowaivers & Biosimilars

Prasad Pasupuleti

Accepted Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.008

Abstract
Recent advances in mammalian cell culture technology has resulted in significant increases in upstream productivity, with antibody titers >5 g/L. Such increases, leading to higher levels of product-related heterogeneous proteins like aggregates, degraded products, processing variants and cell-derived impurities such as host cell protein and DNA. Hence, the development of efficient downstream process is desired to control the impurities as well as to meet the innovator specifications. The entire purification process must be validated by demonstrating a 12 to 20 log reduction of viral load using at least four different model viruses.
Biography
Prasad have been working as Senior Executive in Purification Lab; Biologics Division at Hetero drugs Ltd, Hyderabad, India. At present, He is working on process development of glycosylated proteins and Monoclonal antibodies. Prior, he served for Dr Reddys Laboratories, Intas Biopharmaceutical Ltd and Zenotech Labs in India. Prasad had extensive experience in development of downstream processing, virus clearance studies, scale-up, and process characterization using design of experiments (DOE)
Top